Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lisabeth Buelt"'
Publikováno v:
MDM Policy & Practice, Vol 5 (2020)
Purpose. Assess patient preferences for aspects of breast cancer treatments to evaluate and inform the usual assumptions in scoring rubrics for value frameworks. Methods. A discrete-choice experiment (DCE) was designed and implemented to collect quan
Externí odkaz:
https://doaj.org/article/ac7bd53508bd4e4685060378954844bb
Autor:
Kimberly Westrich, Tasmina Hydery, Vyishali Dharbhamalla, Lisabeth Buelt, Candace Zheng, Victoria Loo, Jennifer Graff
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 29:582-588
Publikováno v:
Journal of managed carespecialty pharmacy. 28(2)
BACKGROUND: Rising health care spending has sparked new efforts to constrain health care expenditures. OBJECTIVE: To explore how health care spending is distributed across consumers and how utiliza...
Autor:
Kimberly Westrich, Lisabeth Buelt
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 26:1452-1454
DISCLOSURES: No funding contributed to the writing of this commentary. The authors have nothing to disclose.
Autor:
Nirosha, Mahendraratnam, Corinna, Sorenson, Elizabeth, Richardson, Gregory W, Daniel, Lisabeth, Buelt, Kimberly, Westrich, Jingyuan, Qian, Hilary, Campbell, Mark, McClellan, Robert W, Dubois
Publikováno v:
The American journal of managed care. 25(2)
To better understand the prevalence of US value-based payment arrangements (VBAs), their characteristics, and the factors that facilitate their success or act as barriers to their implementation.Surveys were administered to a convenience sample of su
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 22(7)
Background Estimates of drug spending are often central to the public policy debate on how to manage healthcare spending in the United States. Nevertheless, common estimates of prescription drug spending vary substantially by source, which can inhibi
Publikováno v:
Journal of managed carespecialty pharmacy. 23(6-a)
As the United States transitions from a volume-based health care system to one that rewards value, new frameworks are emerging to help patients, providers, and payers assess the value of medical services and biopharmaceutical products. These value as